The General Pharmaceutical Council reiterated its stand on Covid-19 vaccination, saying, "Pharmacists and pharmacy technicians working in all settings across Great Britain should be vaccinated against Covid -19, unless they are medically exempt."
In a statement issued today (February 11), it strongly urged all pharmacyprofessionals, students and trainees to get fully vaccinated at the earliest.
This reiteration follows the government's announcement on January 31, 2022 that it would not proceed with Covid vaccination as a mandatory condition of deployment
for health and care staff providing CQC-regulated services in England.
The Council stated that clinical trials have proven the efficacy and safety of Covid vaccines and the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised their use in the UK.
The Pharmacists' Defence Association raised concerns over the practice of firing and rehiring employees, which often leads to denial of individuals' rights to redundancy, forcing them to face cuts to their terms and conditions.
It noted that some employers may use the 'fire and rehire' practice to force staff to accept lower wages, different hours, or other changes in working conditions.
It cited an example of a lawsuit in which Tesco lost a High Court battle when Usdaw won a case to protect workers from unfair tactics.
The PDA said although the trade union won the case, the practice of firing and rehiring can still be legal in some circumstances. However, it believes the practice is both immoral and unethical.
Working conditions in pharmacies have worsened in 2021, the annual Safer Pharmacies Survey conducted by the Pharmacists' Defence Association (PDA) revealed,
highlighting the challenging and unsafe environments that some pharmacists are working in.
The survey asks pharmacists across all areas of practice about their experiences of key safety measures in the workplace.
Since the launch of the Safer Pharmacies Charter in 2017, PDA's annual surveys have monitored their feedback against the Charter's commitments, which covers seven
basic areas as standard practice for pharmacy work.
The commitments are No Self-Checking, Safe Staffing, Access to a Pharmacist, Adequate Rest, Respect for Professional Judgment, Raising Concerns and Physical Safety.
The survey revealed that eight out of 10 feel unsafe at work as violence and abuse still remain areas of concerns in pharmacy.
Deaths caused by hepatitis C has declined by 35 per cent in England between 2015 and 2020, latest data from the UK Health Security Agency (UKHSA) revealed.
It showed that estimated prevalence of chronic hepatitis C in England has continued to fall to around 81,000 in 2020 from 129,000 in 2015, showing a considerable progress has been made towards eliminating the virus as a public health problem by 2030 in England.
Commenting on the data release, health and social care secretary Sajid Javid, said: "It is fantastic to see the significant progress that has been made in eliminating hepatitis C in England. Deaths and prevalence of the virus have fallen consistently thanks to improvements in diagnosis, access to treatments and the hard work of the NHS.
"This is another example of the UK being at the forefront of tackling serious diseases. We are on track to eliminate this virus by 2030 and I urge anyone who may be at risk to get tested as soon as possible."
The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and
diagnostics.
Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy.
This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated.
The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier
and better diagnostic technologies, to medical devices.
The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition.
NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.
Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.
The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
"Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.
The NHS England and Improvement has announced the emergency provisions introduced during pandemic to provide flexible opening hours for pharmacy contractors end today.
The flexibilities were enacted in March 2020 when changes to the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) Directions 2020 were made following a declaration of emergency at the height of the Covid-19 pandemic.
Since March 2020, the flexibilities have permitted temporary opening hours and closures during a specified period due to a genuine Covid-19 related emergency. NHS
England and Improvement has advised pharmacy contractors that the emergency declaration will not be extended further and will expire on 31 March 2022.
Pharmacy contractors will therefore no longer have the option to close pharmacies within their agreed contracted hours with the NHS.
Two pharmacies in Rotherham are set to merge into one, if plans are approved by NHS England.
Weldricks Pharmacy has applied to merge its two Swinton branches, on Church Street and the Crown Street Surgery.
If approved, the branch on Church Street will be modernised, and additional consulting rooms will be added, while the Crown Street site will be closed.
Rotherham Met Borough Council's health and wellbeing board are set to make a representation supporting the plans, and say that analysis by public health "outlines
the very minimal impact that this change will have in terms of pharmacy access in the borough based on the service offer, opening hours and walking times to this
branch and the main pharmacy."
They say the current opening hours will remain the same, and there will be no disruption to services during the consolidation.
A statement from Weldricks adds that the decision to merge is down to funding cuts, and the company could go out of business if operating costs are not reduced -
'despite having been a local, family-owned business for almost 100 years'.
The PSNC on Friday said it has warned the DHSC about the "very serious impact" of the limited supply of certain antibiotics on pharmacies who are "having to
chase stock, purchase without sight of any concession prices, and cope with increasing patient questions and abuse."
With higher than usual number of cases of scarlet fever, caused by invasive Group A Streptococci (iGAS) infections, being reported in children across the country,
supplies of antibiotics for Group A Strep treatment have seen a surge in demand, leading to limited supply at certain wholesalers and pharmacies.
PSNC has urged the DHSC to adopt measures that could help to manage the current crisis, such as allowing pharmacists more freedom to change strengths or formulations
without prescriber approval, outside of Serious Shortage Protocols.
It has also raised concerns on the significant rise in wholesale prices of many oral antibiotics as a result of the surge in demand and the ongoing supply
disruptions. PSNC also said they have received reports of some suppliers putting up their prices for any oral antibiotics they do have in stock.
Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies has said pharmacists have been "struggling to obtain the very basic, most
common cold and flu medicine."
She told the PA news agency that the shortage wasn't around "just the branded medicines" but "also simple things like throat lozenges, cough mixtures or pain
killers - particularly the ones that are soluble."
Stating that the sector was finding it very difficult these shortages she said "those people who are in charge of supporting us with it are denying it."
"The demand has been high because this season we've seen higher cases of colds and flu and people are obviously trying very hard to look after themselves and making
sure that they use the relevant products to manage the symptoms.
The National Pharmacy Association (NPA) has announced the retirement of its Chief Executive, Mark Lyonette.
Mark will retire in 2024. The association has announced his retirement well in advance so that the Board can start work with a leading recruitment agency to search
for the new Chief Executive.
"The Board is keen to build on the strong foundations established and ensure there is a seamless transition and minimum disruption to the business once the new Chief
Executive is in post," said the association.
Mark said: "After five years at the NPA and 40 years working for and leading national membership organisations, I am looking forward to living a different life.
"I am pleased that in the time that I have been with the NPA we have grown both the membership and customer base and created a profitable, stable membership
organisation.
"Alongside our NPA Insurance company, the association is well set to help members face the future.
"Meanwhile there is much to do to ensure that 2023 is another good year in terms of the NPA delivering consistently for members. The process of changing Chief
Executive won't deflect us from our vital work."
Our Totton branch has an incredibly high volume of original pack dispensing, roughly 45,000 items. As we became busier and busier in the dispensary we were
finding that our pharmacists, dispensers and other technicians simply didn't have capacity to deliver the services that we needed them to.
We all know there is a real emphasis right now on pharmacies doing more services and we knew we had to change the way we operate to survive. So we decided it was
time to look into a sound automation solution for our medication dispensing process, one that would allow us to free up the time of the pharmacists and the rest of
the team so they could better support patients.
After a lot of research we invested in Centred Solutions FLOWRx Hub and InStore solutions which were installed late last year. It provides us with the whole package
and has automated our entire dispensing process from picking to packing and labeling to checking.
Our situation was quite unique as we bought the system initially for our existing high-volume pharmacy in Totton so the hub and the spoke are actually on the same
site. People wouldn't usually look at a hub and spoke solution for that kind of set up but it has allowed us to significantly free up time in store for more services.
What it has also done is allow us to look at other opportunities to grow and expand. The pharmacy landscape is changing and there are lots of opportunities coming up.
We have found that having your technology and the right infrastructure in place to support your existing footprint before you expand is the ideal way to grow in a
safe and controlled way.
We never thought that five years ago we would buy another pharmacy, yet we have already bought one and are now in the process of buying two more. I'm not worried
about the increase in volume this expansion will bring because I know our technology is going to be able to support it.
The pharmacies we are buying are struggling but having our solution already in place m
The nationwide implementation of the Pharmacy First service is viewed as a significant development that benefits pharmacies, primary care, and the broader
National Health Service (NHS). Pharmacy teams are striving to ensure its success despite challenges within the industry landscape. However, not all pharmacists
are able to reap the benefits from it.
Recently, two members of Numark shared their experiences of how the scheme is impacting their pharmacies.
Graham Phillips, who owns Letchworth Pharmacy in Hertfordshire, revealed that patients are responding favourably to the service. "It's all good, people are just
delighted to have easier access to care," he said.
In its first month, Letchworth Pharmacy provided around 100 consultations, and Phillips envisions that as the service matures, they will be able to conduct an
average of 200 interventions per week.
"That will make it financially viable for us and mean that we're acting at scale from an NHS perspective. That's 200 GP appointments we've freed up in a
week - that's a huge capability and capacity bump for the NHS," he added.
Graham credits part of his success with Pharmacy First to the strong relationship he has established with local GPs in his area.
Pharmacists, who are working on the frontline of healthcare, can play an important role in raising awareness about mental health and helping those
experiencing poor mental health.
With this belief, the Pharmacists' Defence Association (PDA) is encouraging its representatives at Boots to participate in Mental Health First Aid (MHFA)
training offered by the company.
Nicola Rees, PDA Rep and Boots pharmacist from Solihull, who has recently undertaken training as a Mental Health First Aider, said that trained pharmacists
can help in reducing the stigma associated with mental health and identifying the early warning signs that someone may be experiencing poor mental health.
Mental Health First Aid training enables pharmacists to "support individuals and signpost to sources of advice and support."
Rees expressed that becoming a mental health first aider has empowered her and greatly increased her confidence in being able to support someone dealing with
a mental health issue, such as having thoughts of suicide or self-harm.
The British Generic Manufacturers Association (BGMA) on Monday alerted the Health and Social Care Committee that medicines shortages have increased and
are "around double what they were a year ago."
BGMA chief executive Mark Samuels told the committee that they have been highlighting the medicine shortage risk to ministers since July 2021 and the association
is "very concerned" about the current situation.
"We've been monitoring it for several years now, and as you saw in the written evidence, shortages have increased. They're around double what they were a year ago.
We have them at 101 shortages in February this year," said Samuels.
Dr Rick Greville, director of distribution and supply at the Association of the British Pharmaceutical Industry (ABPI), highlighted that the problem of drug
shortages in the UK is a "long-standing issue" and the scarcity of certain medications "continues to be challenging".
The UK has witnessed a nearly 50 percent increase in pharmacy closures this year compared to the same period in 2023, which was already considered the
worst year in recent memory.
A new analysis by the National Pharmacy Association (NPA) revealed that 177 pharmacies closed their doors between January and April 2024, compared to 116 in the
same period last year. This is the equivalent of 10 local pharmacies shutting down every week.
Analysis of NHS figures by the NPA showed that 403 pharmacies closed their doors last year, nearly five times higher than the number that closed in 2022.
Since 2017, over 1,400 pharmacies have shut down across the UK.
Rising costs and declining real terms funding have led to the fastest rate of closures in decades, said the NPA, highlighting that "real terms funding has
decreased by 40 per cent over the last decade."
The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel
use for patients who have suffered an ischemic stroke or transient ischemic attack.
Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to
guide prescribed antiplatelet medication.
According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test
results and recommending appropriate antiplatelet therapy.
It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke
patients.
The diagnostics advisory committee, a standing advisory committee of NICE, agreed that it should be possible to gather samples for genotype testing at a location
that is convenient for the person having the test and highlighted the role of pharmacies as accessible locations for CYP2C19 genotype testing.The National Institute for Health and Care Excellence (NICE) has published a new diagnostic guidance to enhance CYP2C19 genotype testing to guide clopidogrel
use for patients who have suffered an ischemic stroke or transient ischemic attack.
Published in July, the diagnostic guidance also emphasised the vital role of pharmacists and pharmacies in the implementation of CYP2C19 genotype testing used to
guide prescribed antiplatelet medication.
According to the NICE guidance, pharmacists with their expertise in pharmacogenomics and patient medication management, will be integral in interpreting test
results and recommending appropriate antiplatelet therapy.
It also highlighted the need for close collaboration with other healthcare professionals to ensure effective implementation across various care settings for stroke
patients.
The d
"It is crucial that patients can access care when they need it, whether from a pharmacist or a GP, " Paul Rees, Chief Executive of the National Pharmacy
Association (NPA) has said.
In response to a recent survey conducted by the General Medical Council (GMC) highlighting alarming trends among General Practitioners (GPs), the NPA has issued
a warning about the growing crisis in the UK's primary care system.
Rees emphasised the urgent need for government intervention, saying, "Only by reversing these cuts and providing pharmacies with a new funding deal will we be
able to end the 8am scramble for appointments."
The GMC survey reveals that there is a significant increase in the number of doctors reducing their working hours to safeguard their wellbeing, spotlighting
concerns about the long-term impact on patient care.
According to the report, nearly half of GPs ( 48 per cent) are struggling to manage their workload, with several resorting to decreasing their hours or declining
additional work to protect their mental and physical health.